The Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes
Wang R, Serper M, Taddei T, Kaplan D, Mahmud N. The Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes. The American Journal Of Gastroenterology 2024, 120: 1057-1065. PMID: 39051649, PMCID: PMC12036742, DOI: 10.14309/ajg.0000000000002976.Peer-Reviewed Original ResearchAssociated with hepatic decompensationAngiotensin-converting enzyme inhibitorsAssociated with reduced mortalityAngiotensin receptor blockersACE-I/ARBConverting Enzyme InhibitorsCV-related mortalityHepatocellular carcinomaHepatic decompensationCox regressionAngiotensin receptor blocker exposureEnzyme inhibitorsVeterans Health AdministrationCalcium channel blockersSubsets of patientsChronic liver diseaseCause-specific hazard modelInverse probability treatmentIdentified new initiatorsOutcome of mortalityNew initiativesCirrhosis decompensationCompensated cirrhosisDecompensated cirrhosisChannel blockers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply